Aclaris Therapeutics (ACRS) – Analysts’ Weekly Ratings Changes

Aclaris Therapeutics (NASDAQ: ACRS) has recently received a number of price target changes and ratings updates:

• 10/30/2026 – Aclaris Therapeutics had its price target raised by Canaccord Genuity Group from $10.00 to $13.00. They now have a “buy” rating on the stock.
• 10/28/2026 – Aclaris Therapeutics was given a new $9.00 price target by Craig Hallum.
• 10/28/2026 – Aclaris Therapeutics had its price target lowered by Wedbush from $10.00 to $8.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Aclaris Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
• 10/24/2026 – Aclaris Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/3/2026 – Aclaris Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/21/2026 – Aclaris Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Aclaris Therapeutics Trading Up 9.9%

Aclaris Therapeutics stock traded up $0.36 during mid-day trading on Friday, hitting $3.97. 585,986 shares of the company’s stock were exchanged, compared to its average volume of 2,216,248. Aclaris Therapeutics, Inc. has a 1-year low of $2.10 and a 1-year high of $6.60. The stock has a 50 day moving average of $4.67 and a two-hundred day moving average of $4.54. The stock has a market cap of $554.53 million, a P/E ratio of -6.84 and a beta of 0.96.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. The company had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. As a group, research analysts predict that Aclaris Therapeutics, Inc. will post -0.62 EPS for the current fiscal year.

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.